Fiorenza Santamaria

Email address: fiorenza.santamaria@uniroma1.it

ABOUT ME

M.D., Medical Oncologist
Ph.D. fellow in "Network Oncology and Precision Medicine" at Sapienza University of Rome, Department of Experimental Medicine.

My research focuses on evaluating the impact of drug-drug interactions in clinical practice and optimizing complex therapies by integrating genomic, molecular, and clinico-pathological phenotype data.

During the PhD, I have completed a training period at the Oncology Unit in Pisa (under the supervision of Prof. Chiara Cremolini), focusing on studies involving CRC patients, and at the Bioinformatics Department of Charité – Universitätsmedizin Berlin (under the supervision of Prof. Robert Preissner), where the focus was on complex “drug cocktail” analysis and optimization.

I have a strong expertise in the clinical management of gastrointestinal and genitourinary cancers, as well as in the care of the oncogeriatric population.

I have participated in over fifteen national congresses as a speaker and have organized as a scientific coordinator twelve national congresses, in the past five years.

H-index Scopus: 3
Citation Scopus: 35

WORK EXPERIENCE

RESEARCH ACTIVITY – DEPARTMENT OF MEDICO-SURGICAL SCIENCES AND BIOTECHNOLOGIES – 2026/01/15 – Current – ROMA, ITALY

Research activities, support for data analysis, and statistical processing within the ARSI drug–drug interaction project in prostate cancer.

ONCOLOGIST – VILLA DEL ROSARIO – 2024/07/01 – Current – ROMA, ITALY

EDUCATION AND TRAINING

2009/10/01 – 2015/09/29 Roma, Italy
DEGREE IN MEDICINE AND SURGERY Univ. of Rome “La Sapienza”, Faculty of Medicina e Psicologia

2015/11/01 – 2016/01/31 Roma, Italy
MEDICAL REGISTER IN ROME, POSITION NUMBER: OMCEO ROMA M62285 Univ. of Rome “La Sapienza”, Faculty of Medicina e Psicologia

2017/12/29 – 2023/01/19 Roma, Italy
DOCTOR IN SPECIALIST TRAINING IN MEDICAL ONCOLOGY Univ. of Rome “La Sapienza”, Faculty of Farmacia e Medicina

2023/01/01 – 2025/12/31 Rome, Italy

PHD FELLOW IN "NETWORK ONCOLOGY AND PRECISION MEDICINE" University of Rome "La Sapienza", Dpt. of Experimental Medicine

Expected graduation: March 2026

Thesis Evaluation of Drug-Drug Interactions in Prostate Cancer patients during therapy with Abiraterone, Enzalutamide, Apalutamide or Darolutamide and Docetaxel using the Drug-PIN® software. An interim analysis of the DDI-AID study.

LANGUAGE SKILLS

Mother tongue(s): **ITALIAN**

Other language(s): **ENGLISH**

SKILLS

Excellent command of Office package | Excellent command of statistical analysis software | Good command of the "R" software

PUBLICATIONS

2023

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis

Signorelli, C.; Chilelli, M.G.; et al. Cancers 2023, 15, 5758

2023

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.

Signorelli C., Calegari M.A., et al. Curr. Oncol. 2023, 30, 5456–5469

2024

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis

Michele Basso, Carlo Signorelli, Maria Alessandra Calegari, et al.

2024

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

M. M. Germani, G. Vetere, F. Santamaria, et al.

2024

Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments

Fiorenza Santamaria, Michela Roberto, et al.

2024

Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.

2024
Survival Outcomes with Regorafenib and/or Trifluridine/ Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

Signorelli C., Calegari M.A., et al.

2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study

2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

Signorelli C., Basso M., ..., Santamaria F. et al.

2025
Tyrosine-kinase inhibitors for lung or breast cancer and drug–drug interactions: a clinical guide

Santamaria F., Roberto M., et al.

PROJECTS

2023/11/08 – CURRENT
Evalutation of drug-drug interactions in prostate cancer patients during abiraterone, enzalutamide, apalutamide or darolutamide therapy using drug-pin software. The “DDI-AID” study.

Involvement as Scientific Director and Study Coordinator of the study, approved by the CET Lazio Area 1, Ref. 7364 dated 11/08/2023.

2023/09/04 – CURRENT
Evalutation of clinical impact of drug-drug interactions in metastatic colorectal cancer patients during 5FU-based chemotherapy using Drug-PIN software: a pooled post-hoc analysis of TRIBE and TRIBE2 studies.

2023/08/02 – CURRENT
Real-world data for never resectable mCRC patients during first line chemotherapy - A single Institution experience

Involvement as Scientific Director and Sub-investigator, approved by the CET Lazio area 1, Ref. 7299 del 02/08/2023

CLINICAL AND RESEARCH EXPERIENCE

2023/09/03 – 2024/02/29
Research period at the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa.

Conducted the research project "EVALUATION OF CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS IN METASTATIC COLORECTAL CANCER PATIENTS DURING 5FU-BASED CHEMOTHERAPY USING DRUG-PIN SOFTWARE: A pooled post-hoc analysis of TRIBE and TRIBE2, MOMA, Macbeth, TRIPLETE and Atezo-TRIBE trials" and participated in other activities related to the analysis of data from patients with colorectal cancer under the supervision of Prof. Chiara Cremolini.

2024/03/15 – CURRENT
Authorization for participation in clinical activities for the PhD student.

Participation in clinical and patient-care activities within the framework of the research project titled "Evaluation of drug-drug interactions in patients with prostate cancer undergoing therapy with abiraterone, enzalutamide, or apalutamide using the Drug-Pin software: The 'DDI-AID' study" at the Oncology Unit (UOC) of Policlinico Umberto I.

2025/01/13 – 2025/07/12

Research period at the Department of Bioinformatics, Charité – Universitätsmedizin Berlin.

Conducted research projects and data analyses of studies focused on the evaluation of pharmacological interactions in patients with colorectal and prostate cancer, under the supervision of Prof. Robert Preissner.

HONOURS AND AWARDS

2015/09/29

2013-2015 Percorso di Eccellenza in Translational Medicine – La Sapienza Università di Roma

Research project “Personalized Medicine in patients with Multiple Chemical Sensibility”.
Tutor: prof. Guglielmo Bruno and prof. Maurizio Simmaco.
University of Rome “La Sapienza”, Faculty Of Medicine and Psychology.

2023/10/10

Grant – Università degli Studi di Roma La Sapienza

Project “EVALUTATION OF CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS IN METASTATIC COLORECTAL CANCER PATIENTS DURING 5FU-BASED CHEMOTHERAPY USING DRUG-PIN SOFTWARE: A pooled post-hoc analysis of TRIBE and TRIBE2 studies” approved by S.A. 263/2023 on 10.10.2023.

2024/05/17

Member of "Osservatorio regionale sull'impatto economico delle leggi regionali" – Regione Lazio

2024/07/31

PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA – Policlinico Umberto I, Roma

Tutor “PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA” (Agenas n. 535- 426203, 40 ECM, from 31/07/2024 to 16/12/2024, 2 h/week).

2025/03/03

PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA” – Policlinico Umberto I

Tutor “PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA” (Agenas n. 535- 443655, 50 ECM, from 03/03/2025 to 13/12/2025, 1 h/week).

CERTIFICATIONS

NIDA Clinical Trials Network, 2025/10/23

GOOD CLINICAL PRACTICE Certificate

Expiration Date 23/10/2028

Mode of learning: Online

NETWORKS AND MEMBERSHIPS

2019 – CURRENT

ESMO member

2020 – CURRENT

AIOM member

2024 – CURRENT

ASCO member

ABSTRACT / POSTER IN NATIONAL AND INTERNATIONAL CONGRESS

2023 Abstract and poster

1. POSTER and ABSTRACT ASCO GI 2023: Signorelli C., Schirripa M., [...] Santamaria F., et al. Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study. Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 45-45. DOI: 10.1200/JCO.2023.41.4_suppl.45
2. ABSTRACT and POSTER ESMO 2023: Caira G., Calegari M., [...] Santamaria F., et al. Efficacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis. Ann. Oncol. Vol. 34, Suppl.1, S143, june 2023. https://doi.org/10.1016/j.annonc.2023.04.424
3. ABSTRACT and POSTER ESMO 2023: Trovato G., Valente G., [...], Santamaria F., et al. Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis. Ann. Oncol. Vol. 34, suppl. 1, S140-S141, june 2023. https://doi.org/10.1016/j.annonc.2023.04.416
4. ABSTRACT and POSTER ESMO 2023: Signorelli C., Calegari M., [...], Santamaria F., et al. Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study. Ann. Oncol. Vol. 34, suppl. 1, S85, june 2023. https://doi.org/10.1016/j.annonc.2023.04.251
5. ABSTRACT AIOM 2023: Santamaria F., Buccilli D., et al. Real-world data for never resectable mCRC patients during first line chemotherapy - A single Institution experience. Tumori Journal 109(2): 138
6. ABSTRACT AIOM 2023: Signorelli C., Calegari M.A., [...] Santamaria F., et al. Prognostic and Predictive Effect of Primary Tumor Location on Non-Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Experience" November 2023 Tumori Journal 109(2):133-134
7. ABSTRACT AIOM 2023: Cirillo A., Verrico M., [...] Santamaria F., et al. The impact of immunological age on the response to immunotherapy: a network approach. Tumori Journal 109(2): 259

2024 Abstract and poster

1. POSTER and ABSTRACT ASCO GI 2024. C Signorelli, MG Chilelli, M Basso, MA Calegari, A Anghelone, J Lucchetti, A Minelli, L Angotti, IV Zurlo, M Schirripa, C Morelli, E Dell'Aquila, D Gemma, DC Corsi, G Arrivi, F Zoratto, MG Morandi, **F Santamaria**, R Saltarelli, EM Ruggeri. Survival benefit with regorafenib and/or trifluridine/tipiracil sequencing to rechallenge with anti-EGFR-based third-line regimens in metastatic colorectal cancer: A multicenter retrospective real-world subgroups comparison. May 2024, JCO 42(16). DOI:10.1200/JCO.2024.42.16_suppl.e15553.
2. POSTER and ABSTRACT ESMO GI 2024. C. Signorelli, M.A. Calegari, M. Basso, A. Passardi, J. Lucchetti, I.V. Zurlo, C. Morelli, E. Dell'Aquila, D. Gemma, A. Emiliani, G. Arrivi, F. Zoratto, M.G. Chilelli, M.G. Morandi, **F. Santamaria**, M. Dettori, A. Cosimati, R. Saltarelli, A. Minelli, E.M. Ruggeri. Efficacy Outcomes in ≥70-Year-Old or Younger Patients Receiving Regorafenib-to-Trifluridine/Tipiracil Sequence or vice versa for Refractory Metastatic Colorectal Cancer: Findings from the Multicenter Retrospective "ReTrITA" Study**.** May 2024, Ann of Onc 35(SUPPLEMENT 1):S35. DOI: 10.1016/j.annonc.2024.05.084.
3. AIOM 2024 Abstract & Poster: Signorelli C., Calegari M.A., Basso M., Anghelone A., Passardi A., Zurlo I.V., Lucchetti J., Chilelli M.G., Morelli C., Dell'Aquila E., Gemma D., Ribelli M., Arrivi G., Zoratto F., Morandi M.G., **Santamaria F.**, Saltarelli R., Dettori M., Minelli A., Ruggeri E.M. Prognostic and Predictive Value of Sex in Patients Receiving Regorafenib and/or Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: Real-World Data from the Multicenter Retrospective "ReTrITA" Study". Tumori Journal, Volume 110, Issue 2_suppl: XXVI AIOM National Congress, 8-10 November 2024, Rome (Italy) - Abstract Book

2025 Abstract and poster

1. Abstract ASCO GI 2025: Signorelli C.; ...; **Santamaria F.,** et al. "Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from the multicenter retrospective ReTrITa study.". J Clin Oncol 43, 67-67(2025). DOI: 10.1200/JCO.2025.43.4_suppl.67
2. Abstract & poster ESMO 2025: Signorelli C.; ...; **Santamaria F.,** et al. "Real-World Impact of Frontline Anti-VEGF and Anti-EGFR Exposure on Survival Outcomes with Trifluridine/Tipiracil (without Bevacizumab) and Regorafenib: Findings from the Multicenter Retrospective ReTrITA Study". Annals of Oncology, Volume 36, S540. https://doi.org/10.1016/j.annonc.2025.08.1365
3. Abstract AIOM 2025: **Santamaria F.,** Nicolella F., et al. "Impact of Adjuvant Oxaliplatin-Based Chemotherapy in Elderly Patients with Resected High-Risk Stage II or Stage III Colorectal Cancer: A Single-Institution Experience". Tumori Journal, Vol. 111 N. 2S November 2025
4. Abstract AIOM 2025: Nicolella F., **Santamaria F.,** et al. "Chemotherapy Approach in the Third-Line Setting for Elderly Patients with Metastatic Colorectal Cancer: A Single-Institution Experience". Tumori Journal, Vol. 111 N. 2S November 2025
5. Abstract & poster AIOM 2025: Signorelli C.; ...; **Santamaria F.,** et al. "Impact of First-Line Biologic Exposure on Survival Outcomes in Metastatic Colorectal Cancer Treated with Non-Sequential Trifluridine/Tipiracil and Regorafenib: A Real-World Multicenter Sub-Analysis from the ReTrITA study".Tumori Journal, Vol. 111 N. 2S November 2025

I, Fiorenza Santamaria, hereby declare, pursuant to Italian Presidential Decree no. 445/2000, that the information contained in this curriculum vitae is true and accurate. I am aware of the criminal liability in the event of false statements. I also authorize the processing of my personal data, including sensitive data, in accordance with Legislative Decree no. 196/2003 and EU Regulation 2016/679 (GDPR).

Rome , 2026/02/28

Fiorenza Santamaria
28.02.2026 20:58:37
GMT+02:00